Table 2.

Patient demographic and baseline characteristics

Characteristic	N = 50
Age, years, median (range)	60 (33 – 74)
Sex, Men/Women, n (%)	29 (58)/21 (42)
WHO performance status, n (%)
0	16 (32)
1	29 (58)
2	5 (10)
Time since initial diagnosis of lung cancer, years, n (%)
< 1	13 (26)
1 – 3	23 (46)
≥ 3	13 (26)
Missing	1 (2)
Time since initial diagnosis of brain metastases, years, n (%)
< 1	21 (42)
1 – 3	18 (36)
≥ 3	7 (14)
Missing	4 (8)
Prior antineoplastic therapy for brain metastases, n (%)
Radiotherapy	49 (98)
Surgery	22 (44)
Chemotherapy	16 (32)